Differential expression of miRNAs in colon cancer between African and Caucasian Americans: Implications for cancer racial health disparities

Ellen Li  
*Stony Brook University*

Ping Ji  
*Stony Brook University*

Nengtai Ouyang  
*Stony Brook University*

Yuanhao Zhang  
*Stony Brook University*

Xin Yu Wang  
*Stony Brook University*

*See next page for additional authors*

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

**Recommended Citation**

Li, Ellen; Ji, Ping; Ouyang, Nengtai; Zhang, Yuanhao; Wang, Xin Yu; Rubin, Deborah C.; Davidson, Nicholas O.; Bergamaschi, Roberto; Shroyer, Kenneth R.; Burke, Stephanie; Zhu, Wei; and Williams, Jennie L., "Differential expression of miRNAs in colon cancer between African and Caucasian Americans: Implications for cancer racial health disparities." International Journal of Oncology. 45,2. 587-594. (2014). https://digitalcommons.wustl.edu/open_access_pubs/3047

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Differential expression of miRNAs in colon cancer between African and Caucasian Americans: Implications for cancer racial health disparities

ELLEN LI, PING JI, NENGTAI OUYANG, YUANHAO ZHANG, XIN YU WANG, DEBORAH C. RUBIN, NICHOLAS O. DAVIDSON, ROBERTO BERGAMASCHI, KENNETH R. SHROYER, STEPHANIE BURKE, WEI ZHU and JENNIE L. WILLIAMS

Divisions of 1Gastroenterology, 2Cancer Prevention and 3Colon and Rectal Surgery, Departments of 4Pathology, 5Applied Mathematics and Statistics and 6Preventive Medicine, Stony Brook University, Stony Brook, NY 11794-8160; 7Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO 63110, USA

Received February 27, 2014; Accepted March 26, 2014

DOI: 10.3892/ijo.2014.2469

Abstract. Colorectal cancer (CRC) incidence and mortality are higher in African Americans (AAs) than in Caucasian Americans (CAs) and microRNAs (miRNAs) have been found to be dysregulated in colonic and other neoplasias. The aim of this exploratory study was to identify candidate miRNAs that could contribute to potential biological differences between AA and CA colon cancers. Total RNA was isolated from tumor and paired adjacent normal colon tissue from 30 AA and 31 CA colon cancer patients archived at Stony Brook University (SBU) and Washington University (WU)-St. Louis Medical Center. miRNA profiles were determined by probing human genome-wide miRNA arrays with RNA isolated from each sample. Using repeated measures analysis of variance (RANOVA), miRNAs were selected that exhibited significant (p<0.05) interactions between race and tumor or significant (fold change >1.5, p<0.05) main effects of race and/or tumor. Quantitative polymerase chain reaction (q-PCR) was used to confirm miRNAs identified by microarray analysis. Candidate miRNA targets were analyzed using immunohistochemistry. RANOVA results indicated that miR-182, miR152, miR-204, miR-222 and miR-202 exhibited significant race and tumor main effects. Of these miRNAs, q-PCR analysis confirmed that miR-182 was upregulated in AA vs. CA tumors and exhibited significant race:tumor interaction. Immunohistochemical analysis revealed that the levels of FOXO1 and FOXO3A, two potential miR-182 targets, are reduced in AA tumors. miRNAs may play a role in the differences between AA and CA colon cancer. Specifically, differences in miRNA expression levels of miR-182 may contribute to decreased survival in AA colon cancer patients.

Introduction

In the United States the incidence and mortality rates from colorectal cancer (CRC) are higher in African Americans (AAs) than for all other racial and ethnic groups (1). Socio-economic differences may contribute to delayed detection of cancers. However, a relatively recent study reported that despite receiving equal treatment and after controlling for known prognostic factors, AAs with high-grade tumors were three times more likely to die as a result of CRC than Caucasian Americans (CAs) with high-grade tumors (2). The most recent population-based study shows a 30-50% higher rate of disease-specific mortality after diagnosis among AAs than in CAs (3-8) and this disparity between the 2 groups has greatly widened in recent years. This has occurred despite an increase of CRC screening for both groups. Because one would not expect incidence rates to increase with increased screening and/or detection, it is highly unlikely that socioeconomic status and dietary factors, factors normally attributed to this phenomenon, are the only determinants of racial cancer disparity. Additionally, AAs are diagnosed with CRC at a younger age than Caucasian Americans (CAs) (9). The observation that distinctive mutations in mismatch repair genes hMLH1 and hMSH2 (10), high microsatellite instability (MSI-H), and unique polymorphisms in the p53 tumor suppressor gene (11) are more prevalent in AA colon cancers than in CA colon cancers, lend support to the concept that biological differences between AA and CA tumors may contribute to increased mortality in AA patients.
miRNAs are frequently dysregulated in cancer and have shown promise as tissue-based markers for cancer classification and prognosis (12,13). Initially synthesized as long primary transcripts, miRNA are processed to small (17-22 nt) regulatory RNAs through a series of steps. miRNAs control gene expression via specific sites at the 3'-UTR of their target mRNAs by accelerating mRNA degradation and/or by repression of translation. A number of studies have reported differential expression of miRNAs in paired colon cancer tumor and adjacent normal colon samples (14-21). miRNAs have also been shown to act either as oncogenes [e.g., miR-155, miR-17-5p and miR-21 (22,23)] or as tumor suppressors [e.g., miR-15a, miR-16-1 and let-7 (24)]. In addition, other studies have indicated that miRNAs are involved in tumor migration and invasion (25). Together, these findings support the premise that the dysregulation of miRNAs can lead to the development of cancer.

In this investigation, microarray analysis and qRT-PCR technologies are used to determine whether miRNA levels are disproportionately expressed in the tumors of AA CRC patients as compared to those of CA CRC patients. In this study, we report the identification of miR-182 as a potential candidate that may contribute to increased colon cancer mortality in AA compared to CA patients.

Materials and methods

**Ethics statement.** This study was approved by the Washington University School (WU) of Medicine-St. Louis and Stony Brook University (SBU) Institutional Review Boards. Tissues were banked at the SBU (http://www.stonybrookmedical-center.org/pathology/biobank) and WU (http://www.siteman.wustl.edu/ContentPage.aspx?id=243) human bio-specimen bio-banks. The samples and clinical metadata were de-identified, assigned a patient code and a sample code prior to release to the researchers and qualified for a waiver of consent per 45CFR46.116.d.

**Demographics of colon cancer subjects.** The available clinical metadata for the WU samples were limited to age at the time of surgical resection of the tumor, gender (male vs. female) and race (AA or CA). Paired tumor and normal colon RNA samples were prepared from 30 AA and 31 CA subjects. The average age of the CA (63.4±3.5) and AA (61.3±3.6) subjects were not significantly different. Similarly, the gender distribution was not significantly different for AA (15 male, 14 female and 1 unspecified) and CA (17 male and 14 female) patients.

**Extraction of RNA from SBU and WU colon cancer tumor and adjacent normal colon tissue samples.** For the SBU samples, sections of 30 pairs of formalin-fixed paraffin-embedded (FFPE) tumor and adjacent normal colon tissues were obtained through the Stony Brook Research Histology Core Lab from 15 CA and 15 AA colon cancer patients who underwent colon cancer surgery at Stony Brook University Medical Center. All SBU tissue sections were reviewed by a surgical pathologist (K.R.S.). Tumor sections selected contained a minimum of 70% neoplastic cells, ensuring that the majority of tissue extracted was of neoplastic origin. The control samples were adjacent normal colon tissue removed during colon resection. Total RNA was isolated from three 10-µm thick tissue sections using a miRNeasy FFPE kit (Qiagen, Valencia, CA). Briefly, tumor sections, as determined morphologically by H&E staining, were removed from slides by scraping with a scalpel blade. Paraffin was removed from the sample using xylene and an ethanol wash. Cells were lysed by digestion with proteinase K at 56°C for 15 min followed by additional incubation at 80°C for 15 min. The supernatant was treated with DNase, followed by the addition of Cell Lysis Buffer and ethanol. Total RNA, including miRNA, was bound to an RNeasy MinElute column (Qiagen). The column was washed twice with RPE buffer (Qiagen) and total RNA eluted with RNase-free water.

For the WU sample set, total RNA were prepared by and obtained from the Siteman Cancer Center Tissue Procurement Facility at Washington University (WU)-St. Louis from 16 CA and 15 AA colon cancer patients who underwent colon cancer surgery at Barnes Jewish Hospital. Here, total RNA was extracted from 31 pairs of snap-frozen tumors and adjacent matching normal colon using TRIzol followed by lithium precipitation (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. For all samples, RNA quantity and quality was determined using a Nanodrop 2000C (Thermo Scientific, Waltham, MA).

**Agilent miRNA microarray analysis.** Whole genome miRNA expression profiles for predicting colon cancer risk with respect to race were acquired using single color Agilent miRNA microarrays, release 16.0G4870A 6x60 K (Agilent Technologies, Foster City, CA). miRNAs were labeled and hybridized using Agilent miRNA Complete Labeling and Hybridization Kit (Agilent Technologies) in the Stony Brook University Genomics Core Facility. Labeled miRNA was used to probe and hybridize with Agilent Human Microarray Kit V3, 8x15 K arrays, based on Sanger miRBase release 12.0 (G4470C, Agilent Technologies). Hybridization was performed at 55°C for 20 h in a hybridization oven (Agilent Technologies) according to the manufacturer's protocol. Hybridized microarrays were scanned with a DNA microarray scanner (Agilent G2565BA), and features were extracted using the Agilent Feature Extraction (AFE) image analysis tool (version A.10.7.3.1) with default protocols and settings. To ensure reliable results as to upregulation and downregulation in the miRNAs of a given patient, paired tumor/normal matched samples were run on the same array. All microarray data have been deposited in the NCBI GEO database with accession number GSE48267.

**Microarray preprocessing.** The raw probe-level data were imported into GeneSpring 12.5GX (Agilent Technologies), and the miRNA signal was normalized using the default setting: threshold raw signal to 1.0, percent shift to 90th percentile as the normalization algorithm, and no baseline transformation. After normalization, the probes were filtered using the gIsGeneDetected flag provided in Agilent AFE software to remove miRNAs that were not detected in 60% of tumor or 60% of adjacent normal colon samples. Two class analysis of tumor vs. adjacent normal tissue RNA, AA tumor vs. CA tumor and AA adjacent normal vs. CA adjacent normal were conducted using Significance Analysis of Microarray (26) with a 1.5-fold change and FDR <0.05 for significance.
**qRT-PCR.** For all samples, cDNA was synthesized from 100 ng of total RNA using the Universal cDNA Synthesis Kit (Exiqon, Woburn, MA). After cDNA conversion, quantification of candidate miRNAs (miR-182 and miR204) was determined using commercial specific microRNA LNA PCR primers (Exiqon). Real-time PCR was conducted using Universal RT SYBR Green master mix (Exiqon) in a Realplex real-time PCR machine (Eppendorf, Hauppauge, NY). Quantitative PCR was done under the following cycling conditions: 95°C for 10 min, and 45 cycles of 95°C for 10 s, 60°C for 1 min. All PCRs were done in triplicate. Transcript normalization of samples was obtained using miR-191 as a reference (27). The relative expression of the candidate miRNAs was measured by the threshold cycle Ct miR-191-Ct candidate miRNA. The effects of race, tumor, institutional source and first order interactions were analyzed by RANOVA (see below).

**Immunohistochemistry.** The SBU FFPE tissue sections were deparaffinized and rehydrated according to standard protocols. Tissue sections were pretreated for antigen retrieval by heating in a microwave oven for 15 min in a 0.01 M citric acid solution (pH 6.0). Staining of FFPE colon sections was performed according to the instructions for rapid immunohistochemical staining using Histostain-Plus Bulk Kit (Life Technologies, Grand Island, NY). Primary antibodies to FOXO1 (1:100 dilution/Cell Signaling Technology Inc., Davers, MA) and FOXO3 (1:250/Cell Signaling Technology Inc.) were used to detect these targets of miR-182 and miR-183. An isotypic antibody control was included with each tissue section.

**Scoring.** A pathologist (N.O.), blinded to sample identity, evaluated the SBU tissue sections. The ‘intensity of staining’ of each tissue sample was scored using the following scale: 0, no staining; 1, light staining; 2, medium staining; and 3, maximal staining. Bootstrap RANOVA was used to determine significant differences of FOXO1 and FOXO3α expression by immunohistochemistry.

**Statistical analysis.** Repeated measures analysis of variance (RANOVA) was implemented to evaluate significant effects in the model, with tumor as a within-subjects effect and race and institutional source of the RNA samples as between-subjects effects. Our analysis was based on a mixed model with individual effect on miRNA expression profile as a random effect, and tumor, race and data source as fixed effects: $Y_{ijhkt} = \mu + (\text{Race}_k + \text{Tumor}_j + \text{Source}_h + \text{Sub}_{i(kh)} + \epsilon_{ijhk})$.

Here $Y_{ijhk}$ is the miRNA expression level for subject i, of race indicator h (h=1 or 0 if the subject is AA or CA, respectively), tumor indicator j (j=1 or 0 for tumor or normal tissue, respectively), and source indicator k (k=1 or 0 for SBU or WU, respectively). On the right hand side of the equation, $\mu$ is the overall mean, followed by the race, tumor, source individual effects, two-way and three-way interactions, the random subject effect $\text{Sub}_{i(kh)}$, and the random error $\epsilon_{ijhk}$ independent of $\text{Sub}_{i(kh)}$. Constraints $\sum_{k} \text{Race}_k = \sum_{j} \text{Tumor}_j = \sum_{h} \text{Source}_h = 0$ are imposed for identifiability.

Since normality assumptions did not hold for these datasets, a non-parametric bootstrap approach was adopted to estimate the p-values (28). To further enhance the robustness of the tests, we considered both the p-values and the fold change to test for significance. The threshold was set as fold change >1.5 and p<0.05 for main effects. For interaction terms, the fold change threshold was set at 1.5 for either the AA tumor/CA tumor or the AA normal/CA normal ratio and the p-value threshold was set at 0.05.

**Results**

**The effect of race and tumor on miRNA expression.** Our strategy for selecting candidate miRNAs that could potentially be associated with biological differences between AA and CA colon cancers was to analyze the effect of race and tumor using RANOVA (see Materials and methods). Since the samples obtained from SBU and WU included differences in i) geographic location of the subjects; ii) processing and storage of the tissues (FFPE vs. snap frozen); and iii) RNA isolation procedure, the effect of institutional source was also included. While SAM (26) is extremely robust for two class comparisons, the advantage of RANOVA is that all three terms and first order interactions could be incorporated in the model.

The effect of the tumor was large compared to the effects of race or institutional source. RANOVA identified 49 miRNAs that were upregulated and 40 miRNAs that were downregulated in tumor vs. adjacent normal colonic tissue (Table I). This included the upregulation of a number of miRNAs (e.g., miR-21, miR-31, miR-96 and miR-135b, miR-182, miR-183) (14-19,29-34) and downregulation of miRNAs (e.g., 133a and mir-1) (31) which were previously noted.

As shown in Table II, 4 miRNAs demonstrated significant race:tumor interaction and 5 miRNAs showed both race and tumor main effects. Of the 5 miRNA with both race and tumor main effects, we noted the prominence of miR-182 and miR-204, which were identified based on RANOVA analysis of the SBU miRNA profiles alone (data not shown) and confirmed by the combined data sets. miR-182 was upregulated 11.1-fold in paired tumor vs. normal tissue and was increased 2-fold in AA vs. CA tumors. miR-204 was downregulated 3.6-fold in tumor vs. adjacent normal colonic tissue and increased 2.6-fold in AA vs. CA tumors.

**miR-182 demonstrates a significant race:tumor interactions based on qRT-PCR results.** qRT-PCR using primers for 25 of the miRNAs which were most differentially expressed was conducted to confirm results of the miRNA microarray analysis. The miRNAs which exhibited statistical significance as determined by RANOVA analysis were mir-182 and mir-183 (Fig. 1). Other miRNAs (i.e., mir-135b and mir-204) exhibited significant difference between tumor and normal tissues only. Although the increased expression, as determined by miRNA microarray, of miR-204 in AA tumors compared to CA tumors could not be confirmed by qRT-PCR, our qRT-PCR analysis did confirm that of previous reports indicating downregulation of miR-204 in tumor vs. normal tissues.

RANOVA analysis of only miR-182 and its cluster partner, miR-183 demonstrated a significant race:tumor interaction term (p<0.05, Table III). As demonstrated in Fig. 2, the lines connecting the paired tumor and normal tissues cross, thus graphically demonstrating the interaction between race and tumor in miR-182 qRT-PCR data. The relative level of miR-182 is much higher in the tumor than in the paired adjacent normal.
Table I. miRNAs that were significantly upregulated and downregulated in tumor vs. paired adjacent normal colon tissues.

| Upregulated miRNA | Fold change tumor/normal | p-value | Downregulated miRNA | Fold change tumor/normal | p-value |
|-------------------|---------------------------|---------|----------------------|--------------------------|---------|
| hsa-miR-135b      | 46.25                     | 0       | hsa-miR-133a         | 0.04                     | 0       |
| hsa-miR-183       | 20.00                     | 0       | hsa-miR-139-5p       | 0.07                     | 0       |
| hsa-miR-31        | 17.05                     | 0       | hsa-miR-378*         | 0.09                     | 0       |
| hsa-miR-96        | 11.95                     | 0       | hsa-miR-133b         | 0.10                     | 0       |
| hsa-miR-182       | 11.12                     | 0       | hsa-miR-1            | 0.10                     | 0       |
| hsa-miR-552       | 8.60                      | 0       | hsa-miR-30a*         | 0.11                     | 0       |
| hsa-miR-224       | 5.47                      | 0       | hsa-miR-490-3p       | 0.13                     | 0       |
| hsa-miR-503       | 4.81                      | 0       | hsa-miR-149          | 0.14                     | 0       |
| hsa-miR-18a       | 4.43                      | 0       | hsa-miR-363          | 0.16                     | 0       |
| hsa-miR-17*       | 3.90                      | 0       | hsa-miR-145*         | 0.18                     | 0       |
| hsa-miR-409-3p    | 3.65                      | 0       | hsa-miR-129-3p       | 0.18                     | 0       |
| hsa-miR-424       | 3.49                      | 0       | hsa-miR-143*         | 0.21                     | 0       |
| hsa-miR-203       | 3.42                      | 0       | hsa-miR-145          | 0.23                     | 0       |
| hsa-miR-18b       | 3.38                      | 0.001   | hsa-miR-218          | 0.23                     | 0       |
| hsa-miR-7         | 3.36                      | 0       | hsa-miR-204          | 0.28                     | 0.004   |
| hsa-miR-21'       | 3.24                      | 0       | hsa-miR-143          | 0.29                     | 0       |
| hsa-miR-629''     | 3.15                      | 0       | hsa-miR-23b''        | 0.29                     | 0       |
| hsa-miR-19a       | 2.98                      | 0.001   | hsa-miR-29c''        | 0.31                     | 0       |
| hsa-miR-424''     | 2.91                      | 0       | hsa-miR-338-3p       | 0.33                     | 0       |
| hsa-miR-21        | 2.80                      | 0       | hsa-miR-195          | 0.35                     | 0       |
| hsa-miR-181c      | 2.67                      | 0.002   | hsa-miR-24-1''       | 0.41                     | 0.002   |
| hsa-miR-34b''     | 2.58                      | 0       | hsa-miR-30a          | 0.41                     | 0       |
| hsa-miR-148a      | 2.48                      | 0.003   | hsa-miR-662          | 0.42                     | 0.003   |
| hsa-miR-34a       | 2.28                      | 0.02    | hsa-miR-497          | 0.42                     | 0       |
| hsa-miR-221       | 2.27                      | 0.001   | hsa-miR-99a          | 0.44                     | 0       |
| hsa-miR-146a      | 2.18                      | 0       | hsa-miR-451          | 0.46                     | 0       |
| hsa-miR-301a      | 2.16                      | 0.002   | hsa-miR-28-3p        | 0.48                     | 0       |
| hsa-miR-501-3p    | 2.16                      | 0       | hsa-miR-30e''        | 0.49                     | 0.01    |
| hsa-miR-1246      | 2.10                      | 0.003   | hsa-miR-378          | 0.50                     | 0       |
| hsa-miR-29b       | 2.09                      | 0.004   | hsa-miR-125b-2''     | 0.50                     | 0.002   |
| hsa-miR-130b      | 2.05                      | 0       | hsa-miR-149-2''      | 0.51                     | 0.006   |
| hsa-miR-663b      | 2.04                      | 0.001   | hsa-miR-610          | 0.52                     | 0.015   |
| hsa-miR-20a       | 2.03                      | 0       | hsa-miR-30c-1''      | 0.53                     | 0.005   |
| hsa-miR-296-5p    | 2.03                      | 0       | hsa-miR-100          | 0.56                     | 0       |
| hsa-miR-17        | 1.95                      | 0       | hsa-miR-30c          | 0.57                     | 0       |
| hsa-miR-92a       | 1.89                      | 0       | hsa-miR-193b''       | 0.59                     | 0.044   |
| hsa-miR-429       | 1.85                      | 0.007   | hsa-miR-28-5p        | 0.62                     | 0.006   |
| hsa-miR-19b       | 1.83                      | 0       | hsa-miR-125b         | 0.62                     | 0.002   |
| hsa-miR-335       | 1.78                      | 0.018   | hsa-miR-365          | 0.66                     | 0       |
| hsa-miR-1249      | 1.75                      | 0.044   | hsa-let-7e           | 0.66                     | 0.002   |
| hsa-miR-141       | 1.73                      | 0.035   |                      |                          |         |
| hsa-miR-29a       | 1.68                      | 0       |                      |                          |         |
| hsa-miR-142-3p    | 1.66                      | 0.016   |                      |                          |         |
| hsa-miR-93        | 1.66                      | 0       |                      |                          |         |
| hsa-miR-663       | 1.65                      | 0.002   |                      |                          |         |
| hsa-miR-148b      | 1.59                      | 0.033   |                      |                          |         |
| hsa-miR-425       | 1.58                      | 0.046   |                      |                          |         |
| hsa-miR-25        | 1.57                      | 0       |                      |                          |         |
| hsa-miR-1280      | 1.51                      | 0       |                      |                          |         |

RANOVA was used to identify miRNAs that were differentially expressed (1.5-fold, p<0.05).
colonic tissue. In addition, the relative level of miR-182 is also consistently higher in AA tumors compared to CA tumors in both the SBU and WU cohorts singularly and in combination. Interestingly, there is little or no difference in AA normal mucosa compared to the CA normal tissue.

**Immunohistochemical analysis of potential miRNA targets.** For further downstream analysis, we focused our attention on the potential targets of miR-182 (35,36). We reasoned that upregulation of miR-182 could result in reduced expression of target mRNAs. To test this hypothesis, immunohistochemical

---

### Table II. miRNAs with significant race:tumor interaction or both significant race and tumor main effects.

| Race:tumor | Race | Tumor | Source | Source:race | Source:tumor | Source:race:tumor |
|------------|------|-------|--------|------------|-------------|------------------|
| miR-H1     | 0.016| 0.225 | 0.001  | 0.16       | 0.099       | 0.033            |
| miR-210    | 0.022| 0.226 | 0.001  | 0.074      | 0.441       | 0.297            |
| miR-128    | 0.036| 0.754 | 0.013  | 0.001      | 0.491       | 0.8              |
| miR-200a   | 0.048| 0.452 | 0.022  | 0.278      | 0.974       | 0.905            |
| miR-152    | 0.57 | 0.012 | 0.014  | 0.013      | 0.671       | 0.323            |
| miR-204    | 0.948| 0.013 | 0.004  | 0.239      | 0.288       | 0.841            |
| miR-182    | 0.959| 0.015 | 0      | 0.569      | 0.074       | 0.809            |
| miR-222    | 0.665| 0.017 | 0      | 0          | 0.332       | 0.065            |
| miR-202    | 0.164| 0.045 | 0.017  | 0          | 0.018       | 0.021            |

The p-values for the effect of race, tumor, institutional source of the tissue and all first order interactions were determined using RANOVA (see Materials and methods). The threshold for significance was set as p<0.05.

---

### Table III. RANOVA analysis of qRT-PCR analysis of selected miRNA expression relative to miR-191.

| Race:tumor | Race | Tumor | Source | Source:race | Source:tumor | Source:race:tumor |
|------------|------|-------|--------|------------|-------------|------------------|
| hsa-miR-182| 0.001| 0.325 | 0      | 0          | 0.905       | 0.058            |
| hsa-miR-204| 0.439| 0.898 | 0      | 0.038      | 0.028       | 0.053            |
| hsa-miR-183| 0.048| 0.048 | 0      | 0.473      | 0.473       | 0.189            |

---

Figure 1. Confirmation by qRT-PCR analysis of miRNAs that were most differentially expressed. qRT-PCR analysis using primers for 25 of the most differentially expressed miRNAs were evaluated. Statistical significance was determined by RANOVA (p<0.05). Significance was as follows: (A) miR-182, CAN vs. AAT, CAT vs. AAT and AAN vs. AAT. (B) miR-183, CAN vs. AAT, CAT vs. AAT and AAN vs. AAN. (C) miR-135b, CAN vs. CAT and AAN vs. AAT. (D) miR-204, CAN vs. CAT and AAN vs. AAT. Abbreviations: CA, Caucasian American; AA, African American; T, tumor; and N, normal adjacent.
staining for two potential miR-182 targets, FOXO1 and FOXO3a, were performed on 10 of the 15 matching tissue sets from SBU CA and AA colon cancer patients (Fig. 3). SBU samples were solely used due to availability of samples for this analysis. FOXO1 and FOXO3a cytoplasmic staining was detected in all normal colon tissue samples regardless of race. In normal colonic mucosa, staining for both FOXO1 and FOXO3a was most intense in luminal surface columnar cells, but colonic crypt epithelial cells also showed weak to moderate cytoplasmic staining. In tumors, FOXO1 was localized exclusively in the cytoplasm, but FOXO3a showed nuclear staining, potentially reflecting the translocation of phospho-FOXO3a. The expression of FOXO1 decreased by 57.14% in tumors of CAs and decreased by 83.33% in tumors of AAs as compared to adjacent normal tissues. Similarly, the extent of expression of FOXO3a decreased by 41.17% in tumors of CAs and decreased by 65.22% in tumors of AAs as compared to adjacent normal tissues. However, the trend towards reduced staining in AA tumors compared to CA did not reach statistical significance. Statistical significance was noted only when assessing differences in staining between normal and tumor tissues.
Discussion

This exploratory study provides proof of principle for identifying biological factors that could contribute to increased mortality in CRC in AAs compared to CAs. Whole human genome miRNA expression profiles were compared between AA and CA paired colon cancer and adjacent normal colonic tissue. To increase the power of the analysis, samples were combined between two medical centers located, respectively, in New York City, NY and St. Louis, MO, with at least 30 subjects per each racial cohort. The 2 cohorts were not significantly different with respect to distribution of age or gender. However, there were significant differences between the 2 cohorts with respect to the type of samples used: formalin fixed paraffin embedded tissues vs. snap frozen tissues.

One approach towards identifying candidate miRNAs could be to conduct a series of two class comparisons using SAM (26); i) compare paired tumor vs. adjacent normal; ii) compare unpaired AA tumor with CA tumor; and iii) compare unpaired AA normal with CA normal. The miRNAs that were differentially expressed in tumor vs. normal and between AA cancer and CA cancer would be selected as potential candidates. However, to simultaneously evaluate the effect of race, tumor and the institutional source as well as first order interaction terms we instead used RANOVA.

The largest differences in miRNA expression are between tumor and adjacent normal tissue. RANOVA identified miRNAs that were previously reported to be differentially expressed between tumor and normal colon tissue (14-19,29-34). RANOVA identified nine miRNAs that exhibited either a race:tumor interaction or both race and tumor main effects. We focused on one miRNA that were initially identified by both SAM and RANOVA analysis in the SBU cohort and then confirmed in the analysis of the combined SBU and WU cohorts. Our main potential biomarker for indicating a role in racial disparity, miR-182, has been previously reported to be upregulated in tumor vs. normal tissues. In addition, miR-204, which has been previously reported to be downregulated in tumors (29-34) was also considered as a potential biomarker. While subsequent qRT-PCR confirmed upregulation of miR-182 and downregulation of miR-204 in tumor vs. normal tissues, only miR-182 was confirmed as being increased in AA vs. CA tumor tissues. In agreement, analysis of miR-182 expression in the 6 AA designated colon cancers and the 37 CA designated colon cancers in The Cancer Genome Atlas database also showed increased expression in the AA cancers, but this increase did not reach statistical significance (37). This could be due in part to the small sample number of AA colon cancer tissue. A recent RT-PCR analysis of selected miRNAs in AA and CA paired tumor and adjacent normal colon tissues detected an effect of race and colon cancer stage on expression; however, miR-182 was not measured in this study (38). While the observation that miR-182 expression is increased in AA tumors, needs to be confirmed in larger samples sets and/or better annotation of racial metadata in existing collections, the results of this study suggests that variations in sample processing at different institutions will not obscure racial differences in miRNA expression.

In accordance with the expression levels of miR-182, there were reduced expressions of FOXO3 and FOXO1 in tumor vs. normal tissues in the SBU cohort. Although expression levels were noted to differ between AA vs. CA tumors, this decreased expression was not statistically significant. These immunohistochemical results support a recent report of decreased FOXO3a (39) expression in CRC, and suggest that miR-182 levels may contribute to the regulation of FOXO1 and FOXO3a expression. The concept that increased miR-182 levels in AA compared to CA levels may contribute to increased AA colon cancer mortality is further supported by a recent report linking miR-182 to reduced colon cancer survival and increased liver metastases (40). Targeted suppression of miR-182 expression has been reported to reduce hepatic metastases in an experimental model of melanoma (41), suggesting that miR-182 is involved in promoting the development of liver metastases.

The molecular pathways leading AA colon cancer racial health disparity remain to be determined. We propose that this may be related to an increase of miR-182 in AA colon cancers. One potential link may be with defective mismatch repair (19). AAs with CRC (43%) have a higher proportion of MSI instability compared to the general US population (42). This instability may in turn be associated with altered prognosis and response to chemotherapeutic agents (42). Another may be epigenetic modulation of the miR-182 locus (43). Identification of the biological pathways associated with differential expression of miRNAs in AA cancers will, therefore, require the generation and integration of parallel genetic and epigenetic miRNA expression datasets with an expanded racially annotated miRNA colon cancer dataset.

Acknowledgements

We thank the Siteman Cancer Center Tissue Core (Washington University, St. Louis, MO) for providing the total RNA isolated from colon cancer tissues for microarray analysis. The Siteman Cancer Center is supported in part by NCI Cancer Center Support Grant #P30 CA91842. Technical support for histologic studies was provided by the Stony Brook Medicine Research Histology Core Lab. We thank John Schwedes in the Stony Brook University Genomics Core Facility for conducting the labeling, hybridization and scanning of the microarrays. The authors thank Ms. Patti Blair (Blair Biosciences, LLC) for editorial assistance. This study was supported by the grants R01CA140487 and DK52574 and The Simons Foundation.

References

1. Lieberman DA, Holub JL, Moravec MD, Eisen GM, Peters D and Morris CD: Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA 300: 1417-1422, 2008.
2. Alexander D, Jhala N, Chatla C, et al: High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colon adenocarcinomas. Cancer 103: 2163-2170, 2005.
3. Chien C, Morimoto LM, Tom J and Li C: Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer 104: 629-639, 2005.
4. Clegg LX, Li FP, Hankey BF, Chu K and Edwards BK: Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 162: 1985-1993, 2002.
5. Cooper GS, Yuan Z and Rimm EA: Racial disparity in the incidence and case-fatality of colorectal cancer: analysis of 329 United States counties. Cancer Epidemiol Biomarkers Prev 6: 283-285, 1997.
6. Hodgson DC, Fuchs CS and Ayanian JZ: Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93: 501-515, 2001.
7. Hodgson DC, Zhang W, Zaslavsky AM, Fuchs CS, Wright WE and Ayanian JZ: Relation of hospital volume to colonoscopy rates and survival for patients with rectal cancer. J Natl Cancer Inst 95: 708-716, 2003.

8. Mayberry RM, Coates RJ, Hill HA, et al: Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst 187: 1686-1693, 1995.

9. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A and Edwards BK (eds): SEER Cancer Statistics Review, 1973-1994. National Cancer Institute, Bethesda, MD, 1997.

10. Weber TK, Chin HM, Rodriguez-Bigas M, et al: Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer. JAMA 281: 2316-2320, 1999.

11. Carethers JM: Racial and ethnic factors in the genetic pathogenesis of colorectal cancer. J Assoc Acad Minor Phys 10: 59-67, 1999.

12. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ and Kerin MF: MicroRNAs as novel biomarkers for breast cancer. J Oncol 2009: 950201, 2009.

13. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.

14. Yang L, Belaguli N and Berger DH: MicroRNA and colorectal cancer. World J Surg 33: 638-646, 2009.

15. Cummins JM, He Y, Leary RJ, et al: The colorectal microRNAome. Proc Natl Acad Sci USA 103: 3687-3692, 2006.

16. Callari M, Dugo M, Musella V, et al: Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS One 7: e45105, 2012.

17. Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436, 2008.

18. Schepeler T, Reinert JT, Ostenfeld MS, et al: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424, 2008.

19. Sarver AL, French AJ, Borralho PM, et al: Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9: 401, 2009.

20. Xi Y, Shalgi R, Fodstad O, Pilpel Y and Ju J: Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 12: 2014-2024, 2006.

21. Fu J, Tang W, Du P, et al: Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol 6: 68, 2012.

22. He L, Thomson JM, Hemann MT, et al: A microRNA polysiontron as a potential human oncogene. Nature 435: 828-833, 2005.

23. Voorhoeve PM, le Sage C, Schrier M, et al: A genetic screen implicates miR-372 and miR-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169-1181, 2006.

24. Shell S, Park SM, Radjabi AR, et al: Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104: 11400-11405, 2007.

25. Huang Q, Gumireddy K, Schrier M, et al: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10: 202-210, 2008.

26. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121, 2001.

27. Peltier HJ and Latham GF: Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844-852, 2008.

28. Zhou BY and Wong WH: A bootstrap-based non-parametric ANOVA method with applications to factorial microarray data. Statistica Sinica 21: 495-514, 2011.

29. Xu XM, Qian JC, Deng ZL, et al: Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett 4: 339-345, 2012.

30. Meiri E, Levy A, Benjamin H, et al: Discovery of microRNAs and other small RNAs in solid tumors. Nucleic Acids Res 38: 6234-6246, 2010.

31. Reid JF, Sokolova V, Zoni E, et al: miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res 10: 504-515, 2012.

32. Hamfjord J, Stangeland AM, Hughes T, et al: Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One 7: e34150, 2012.

33. Piepoli A, Tavano F, Copetti M, et al: MiRNA expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One 7: e33663, 2012.

34. Liu H, Du L, Wen Z, et al: Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis 28: 697-703, 2013.

35. Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859, 2007.

36. Paik JH, Kollipara R, Chu G, et al: FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323, 2007.

37. CGA N: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337, 2012.

38. Bovell LC, Shanmugam C, Putcha BD, et al: The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res 19: 3955-3965, 2013.

39. He LY, Wei X, Du L, et al: Remarkably reduced expression of FoxO3a in metastatic colorectum, primary colorectal cancer and liver metastasis. J Huazhong Univ Sci Technolog Med Sci 33: 205-211, 2013.

40. Huynh C, Segura MF, Gazieli-Sovran A, et al: Efficient in vivo microRNA targeting of liver metastasis. Oncogene 30: 1481-1488, 2011.

41. Kauh J, Brawley OW and Berger M: Racial disparities in colorectal cancer. Curr Probl Cancer 31: 123-133, 2007.

42. Carethers JM, Chauhan DP, Fink D, et al: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131, 1999.

43. Liu S, Howell PM and Riker AI: Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells. Ann Surg Oncol 20: 1745-1752, 2013.